Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

MBCProject_0381_T1_RNA

· B

4572344c-c404-54aa-a1de-c1816cc9c5ca

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.320
  • G2M_CHECKPOINT+0.220
  • E2F_TARGETS+0.200
  • MITOTIC_SPINDLE+0.070
  • GLYCOLYSIS-0.010
  • DNA_REPAIR-0.020
  • ESTROGEN_RESPONSE_EARLY-0.020
  • ESTROGEN_RESPONSE_LATE-0.070
  • MYC_TARGETS_V1-0.120
  • UNFOLDED_PROTEIN_RESPONSE-0.120

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.550
  • INTERFERON_GAMMA_RESPONSE-0.530
  • COMPLEMENT-0.520
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.510
  • ANGIOGENESIS-0.490
  • COAGULATION-0.470
  • IL6_JAK_STAT3_SIGNALING-0.470
  • INFLAMMATORY_RESPONSE-0.460
  • TGF_BETA_SIGNALING-0.450

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1BS_D0RDN4K5
brain-umap@2
Embryonal tumors0.936
2SAMN03290905
melanoma-umap@29
0.934
3BS_A87NPZAP
brain-umap@2
medulloblastoma0.927
4BS_1BWP5MCT
brain-umap@2
medulloblastoma0.923
5BS_4W68NV3M
brain-umap@2
medulloblastoma0.920
6SRR8518343
breast-umap@18
E0.918
7SRR650166
bladder-landscape@3
0.916
8BS_3NWQXPQV
brain-umap@2
medulloblastoma0.912
9c01b5135.b754.4c57.a81d.68a951803fab
lung-landscapes@6
cohortMD10.910
10SRR1324452
brain-umap@2
GTEX0.904

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 4 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.320Idelalisib— uncovered
G2M_CHECKPOINT0.220Inavolisib— uncovered
E2F_TARGETS0.200Inavolisib— uncovered
MITOTIC_SPINDLE0.070Inavolisib— uncovered